Education
About Us
Working with TipRanks
Follow Us
Theriva Biologics (TOVX)
:TOVX
TOVX Stock Chart & Stats
$0.20
-$0.06(-3.70%)
At close: 4:00 PM EST
$0.20
-$0.06(-3.70%)
Day’s Range― - ―
52-Week Range$0.20 - $2.08
Previous CloseN/A
Volume37.66K
Average Volume (3M)8.88M
Market Cap
$7.33M
Enterprise Value-$6.30M
Total Cash (Recent Filing)$7.53M
Total Debt (Recent Filing)$2.76M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Apr 01, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding33,739,643
10 Day Avg. Volume25,882,304
30 Day Avg. Volume8,875,558
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.12
Price to Sales (P/S)0.00
P/FCF Ratio-0.14
Enterprise Value/Market Cap-0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit233.32
Enterprise Value/Ebitda0.24
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PositionTheriva has a cash runway into the fourth quarter of 2025, supported by an additional $7.5 million raised from equity financing.
Market InterestThe oncolytic virus space has been gaining traction with investors and is poised for an active period, with Theriva's VCN-01 approach being differentiated and having orphan drug and fast track designations for pancreatic cancer.
Pipeline PotentialVCN-01 has the potential to resensitize tumors to other therapies by degrading tough stromal tissue, which could be advantageous in treating pancreatic cancer.
Bears Say
Clinical Development UncertaintyThe path forward for VCN-01 is unclear, with uncertainty about whether it will progress to a Phase 3 study or if the dosing needs further exploration.
Clinical Study ResultsThe overall data from the P2b pancreatic cancer study was mixed and unimpressive, particularly because the key measure of median overall survival did not meet expectations.
Stock PerformanceThe shares of Theriva Biologics experienced a significant drop of 40% due to the unimpressive data results and concurrent equity financing.
Theriva Biologics News
TOVX FAQ
What was Theriva Biologics’s price range in the past 12 months?
Theriva Biologics lowest stock price was $0.20 and its highest was $2.08 in the past 12 months.
What is Theriva Biologics’s market cap?
Theriva Biologics’s market cap is $7.33M.
When is Theriva Biologics’s upcoming earnings report date?
Theriva Biologics’s upcoming earnings report date is Apr 01, 2026 which is in 105 days.
How were Theriva Biologics’s earnings last quarter?
Theriva Biologics released its earnings results on Nov 12, 2025. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.38 by -$0.07.
Is Theriva Biologics overvalued?
According to Wall Street analysts Theriva Biologics’s price is currently Overvalued.
Does Theriva Biologics pay dividends?
Theriva Biologics does not currently pay dividends.
What is Theriva Biologics’s EPS estimate?
Theriva Biologics’s EPS estimate is -0.5.
How many shares outstanding does Theriva Biologics have?
Theriva Biologics has 33,739,643 shares outstanding.
What happened to Theriva Biologics’s price movement after its last earnings report?
Theriva Biologics reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.38. Following the earnings report the stock price went up 7.143%.
Which hedge fund is a major shareholder of Theriva Biologics?
Currently, no hedge funds are holding shares in TOVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theriva Biologics
Theriva Biologics (TOVX) is a biotechnology company focused on the development and commercialization of therapeutics for cancer and other diseases. The company's core products involve the use of oncolytic viruses and live microbial therapeutics to enhance the efficacy of existing treatments and improve patient outcomes. By leveraging innovative biologic technologies, Theriva Biologics aims to address unmet medical needs and offer new solutions in oncology and other therapeutic areas.
TOVX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Galmed Pharmaceuticals
―
Matinas BioPharma
―
Qualigen Therapeutics
―
CNS Pharmaceuticals
―
Galecto
―
Ownership Overview
0.77%
Insiders
0.10% Mutual Funds
0.47% Other Institutional Investors
98.62% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---